Next Article in Journal
Postoperative Delirium in Patients with Oral Cancer: Is Intraoperative Fluid Administration a Neglected Risk Factor?
Next Article in Special Issue
Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry
Previous Article in Journal
How Many Private Data Are Needed for Deep Learning in Lung Nodule Detection on CT Scans? A Retrospective Multicenter Study
Previous Article in Special Issue
Male Breast Cancer: From Molecular Genetics to Clinical Management
 
 
Review

Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer

1
School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
2
Aberdeen Royal Infirmary, Department of Oncology, Foresterhill Road, Aberdeen AB25 2ZN, UK
3
Aberdeen Royal Infirmary, Breast Unit, Foresterhill Road, Aberdeen AB25 2ZN, UK
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Dik C. van Gent
Cancers 2022, 14(13), 3175; https://doi.org/10.3390/cancers14133175
Received: 20 May 2022 / Revised: 24 June 2022 / Accepted: 24 June 2022 / Published: 28 June 2022
Male breast cancer (MBC) is an orphan disease that is on the rise but remains understudied. Mutations in genes sensitive to DNA damage response, BRCA1 and BRCA2, are strongly implicated in MBC development. Evidence-based guidance for the treatment of MBC that have BRCA mutations is lacking with most published data arising from retrospective or case studies with small patient cohorts. Here, we review the lack of treatment evidence for BRCA-related MBC. We also highlight the impact of poly(ADP-ribose) polymerase (PARP) inhibitors which are used in the clinical management of BRCA-related female breast cancer and prostate cancer. In turn, we demonstrate the requirement for national and global collaborative efforts to address the striking unmet need for dedicated BRCA-related MBC research, including studies to better understand disease trajectory and improve clinical outcomes.
Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all breast cancers and male malignancies. Despite recognised clinico-pathological and molecular differences to female breast cancer (FBC), the clinical management of MBC follows established FBC treatment strategies. Loss of function mutations in the DNA damage response genes BRCA1 and BRCA2, have been strongly implicated in the pathogenesis of MBC. While there have been extensive clinical advancements in other BRCA-related malignancies, including FBC, improvements in MBC remain stagnant. Here we present a review that highlights the lack of treatment evidence for BRCA-related MBC and the required national and global collaborative effort to address this unmet need. In doing so, we summarise the transformative clinical advancements with poly(ADP-ribose) polymerase (PARP) inhibitors in other BRCA-related cancers namely, FBC and prostate cancer. View Full-Text
Keywords: male breast cancer; BRCA; clinical management; PARP inhibitors male breast cancer; BRCA; clinical management; PARP inhibitors
MDPI and ACS Style

McClurg, D.P.; Urquhart, G.; McGoldrick, T.; Chatterji, S.; Miedzybrodzka, Z.; Speirs, V.; Elsberger, B. Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer. Cancers 2022, 14, 3175. https://doi.org/10.3390/cancers14133175

AMA Style

McClurg DP, Urquhart G, McGoldrick T, Chatterji S, Miedzybrodzka Z, Speirs V, Elsberger B. Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer. Cancers. 2022; 14(13):3175. https://doi.org/10.3390/cancers14133175

Chicago/Turabian Style

McClurg, Dylan P., Gordan Urquhart, Trevor McGoldrick, Subarnarekha Chatterji, Zosia Miedzybrodzka, Valerie Speirs, and Beatrix Elsberger. 2022. "Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer" Cancers 14, no. 13: 3175. https://doi.org/10.3390/cancers14133175

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop